Title : NKG2A Down-Regulation by Dasatinib Enhances Natural Killer Cytotoxicity and Accelerates Effective Treatment Responses in Patients With Chronic Myeloid Leukemia.

Pub. Date : 2018

PMID : 30705677






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 ABL tyrosine kinase inhibitors (TKIs), such as imatinib, nilotinib, and dasatinib, are currently the front-line treatment options for CML. Dasatinib ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens
2 Our results highlight the dual effects of dasatinib in direct inhibition of ABL kinase and in immunomodulation through NKG2A down-regulation, contributing to accelerated molecular responses (MR) in CML. Dasatinib ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens